[Sinovac Announces Preliminary Results of Phase III Trial on sIPV BEIJING, April 19, 2018 -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactiva]
[Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd. - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary – - Reaffirms Commitment to Take All Appropriate Actions to Protect Compan]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 ☒ ☐ ☐ (Check One): ☐ ☐ ☐ For Period Ended: December 31, 2017 ☐ ☐ ☐ ☐ ☐ For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained he]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 ☒ ☐ ☐ (Check One): ☐ ☐ ☐ For Period Ended: December 31, 2017 ☐ ☐ ☐ ☐ ☐ For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained he]
[] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD84,849.59 respectively as of December 31, 2017. Due to the fact the Company temporarily did]
[] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD84,849.59 respectively as of December 31, 2017. Due to the fact the Company temporarily did]
[Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction BEIJING, March 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that on March 26, 2018, it entered]
[Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction BEIJING, March 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that on March 26, 2018, it entered]
[SCHEDULE 13D (Amendment No. 1)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares (Title of Class of Securities) P8696W104 (CUSIP Number) 1Globe Capital LLC One International Place, 44th Floor Boston, MA 02110 (617) 894-8436 (Name, Address and Telephone Number of Person Authorized to Receive Notic]
[SCHEDULE 13D (Amendment No. 1)* SINOVAC BIOTECH LTD. (Name of Issuer) Common Shares (Title of Class of Securities) P8696W104 (CUSIP Number) 1Globe Capital LLC One International Place, 44th Floor Boston, MA 02110 (617) 894-8436 (Name, Address and Telephone Number of Person Authorized to Receive Notic]
